You are here

Do Thiopurines Reduce the Risk of Surgery in Elderly Onset Inflammatory Bowel Disease? A 20-Year National Population-Based Cohort Study.

Do Thiopurines Reduce the Risk of Surgery in Elderly Onset Inflammatory Bowel Disease? A 20-Year National Population-Based Cohort Study. Inflamm Bowel Dis. 2017 Feb 01;: Authors: Alexakis C, Saxena S, Chhaya V, Cecil E, Curcin V, Pollok R Abstract BACKGROUND: Evidence that thiopurines impact on the risk of surgery in elderly onset inflammatory bowel disease (EO-IBD) is lacking. We aimed to compare the rates of surgery in EO-IBD (>60 years at diagnosis) with adult-onset IBD (18-59 yrs), and examine the impact of thiopurines on surgical risk in EO-IBD. METHODS: Using…

Read More

Nodular Regenerative Hyperplasia of the Liver in Patients with IBD Treated with Allopurinol-Thiopurine Combination Therapy.

Nodular Regenerative Hyperplasia of the Liver in Patients with IBD Treated with Allopurinol-Thiopurine Combination Therapy. Inflamm Bowel Dis. 2017 Feb 01;: Authors: Seinen ML, van Asseldonk DP, de Boer NK, Bouma G, van Nieuwkerk CM, Mulder CJ, Bloemena E, van Bodegraven AA Abstract BACKGROUND: Thiopurine therapy, particularly thioguanine, has been associated with nodular regenerative hyperplasia (NRH) of the liver. Combination therapy of allopurinol and an adapted low-dose thiopurine leads to a pharmacokinetic profile that has similarities to that of thioguanine. Therefore, allopurinol-thiopurine combination therapy may also be associated with NRH…

Read More

Methotrexate for Refractory Crohn’s Disease Compared with Thiopurines: A Retrospective Non-head-to-head Controlled Study.

Methotrexate for Refractory Crohn’s Disease Compared with Thiopurines: A Retrospective Non-head-to-head Controlled Study. Inflamm Bowel Dis. 2017 Jan 26;: Authors: Huang Z, Chao K, Li M, Zhi M, Tang J, Hu P, Gao X Abstract BACKGROUND: This study assessed the efficacy and safety of methotrexate (MTX) compared with thiopurines (TPs) for refractory Crohn’s disease. METHODS: Fifty-one consecutive patients who were refractory or intolerant to TPs and steroid-dependent were retrospectively analyzed. MTX (20 mg/wk, subcutaneous) was adopted for inducing and maintaining clinical remission (CR). Fifty-seven patients who were naive to immunosuppressant…

Read More

O-005 Combination Therapy with Methotrexate Does Not Change Infliximab Pharmacokinetics in Children with Inflammatory Bowel Disease.

O-005 Combination Therapy with Methotrexate Does Not Change Infliximab Pharmacokinetics in Children with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 Feb;23 Suppl 1:S2 Authors: Shakhnovich V, Van Haandel L, Becker M, Funk R Abstract BACKGROUND: There remains a question of equipoise regarding the use of anti-TNF-α agent (e.g., infliximab) monotherapy versus combination therapy with immunomodulators (e.g., methotrexate), for the treatment of pediatric Inflammatory Bowel Disease (IBD). The aim of this prospective cross-sectional study was to assess the impact of methotrexate (MTX) on infliximab (IFX) pharmacokinetics (i.e., serum trough levels) and…

Read More

Prevalence and Risk Factors for Symptoms of Methotrexate Intolerance in Pediatric Inflammatory Bowel Disease.

Prevalence and Risk Factors for Symptoms of Methotrexate Intolerance in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 Feb;23(2):298-303 Authors: Dupont-Lucas C, Grandjean-Blanchet C, Leduc B, Tripcovici M, Larocque C, Gervais F, Jantchou P, Amre D, Deslandres C Abstract BACKGROUND: Methotrexate (MTX) intolerance is defined as gastrointestinal and behavioral symptoms occurring before or after MTX administration that may lead to treatment discontinuation. The aim of this study was to determine prevalence of MTX intolerance in pediatric inflammatory bowel disease (IBD) using the Methotrexate Intolerance Severity Score developed in rheumatology and…

Read More

Efficacy of additional treatment with azathioprine in a patient with prednisolone-dependent gastric sarcoidosis.

Related Articles Efficacy of additional treatment with azathioprine in a patient with prednisolone-dependent gastric sarcoidosis. World J Gastroenterol. 2016 Dec 21;22(47):10471-10476 Authors: Murata M, Sugimoto M, Yokota Y, Ban H, Inatomi O, Bamba S, Kushima R, Andoh A Abstract Gastric sarcoidosis with noncaseating granuloma is rare. Although corticosteroid produces a dramatic clinical response, it is unknown whether azathioprine show efficacy in prednisolone-dependent cases. Here, we report a case of gastric sarcoidosis in a 25-year-old man with severe epigastlargia. Gastroendoscopy revealed multiple map-like ulcerations. Histological examination showed multiple noncaseating granulomatous lesions…

Read More

Hepatosplenic T-cell lymphoma in a 47-year-old Crohn’s disease patient on thiopurine monotherapy.

Related Articles Hepatosplenic T-cell lymphoma in a 47-year-old Crohn’s disease patient on thiopurine monotherapy. World J Gastroenterol. 2016 Dec 21;22(47):10465-10470 Authors: van de Meeberg MM, Derikx LA, Sinnige HA, Nooijen P, Schipper DL, Nissen LH Abstract Hepatosplenic T-cell lymphoma (HSTCL) is a rare non-Hodgkin lymphoma with a high mortality rate. Higher incidence is reported in patients with inflammatory bowel disease, specifically in male patients that are younger than 35 years, and have been treated with thiopurine and tumor necrosis factor (TNF)-α inhibitor combination therapy for over 2 years. In this…

Read More

Thiopurines and inflammatory bowel disease: Current evidence and a historical perspective.

Related Articles Thiopurines and inflammatory bowel disease: Current evidence and a historical perspective. World J Gastroenterol. 2016 Dec 14;22(46):10103-10117 Authors: Axelrad JE, Roy A, Lawlor G, Korelitz B, Lichtiger S Abstract The use of thiopurines in inflammatory bowel disease (IBD) has been examined in numerous prospective, controlled trials, with a majority demonstrating a clinical benefit. We conducted this review to describe the historical and current evidence in the use of thiopurines in IBD. A systematic search was performed on MEDLINE between 1965 and 2016 to identify studies on thiopurines in…

Read More

The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease.

Related Articles The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2016 Dec 19;: Authors: Carrat F, Seksik P, Colombel JF, Peyrin-Biroulet L, Beaugerie L, CESAME Study Group Abstract BACKGROUND: Whether aminosalicylates or thiopurines reduce the risk of colorectal cancer (CRC) in inflammatory bowel (IBD) disease is controversial. AIM: To assess simultaneously the chemopreventive effect of aminosalicylates or thiopurines in a case-control study nested in the CESAME observational cohort that enrolled consecutive patients with IBD between May 2004 and June…

Read More
<< Go Back